BMS-986310 + nivolumab

BMS-986310 + nivolumab is an investigational combination therapy in clinical development for advanced solid tumors. **BMS-986310** is a small-molecule antagonist of the **prostaglandin E2 receptor 4 (EP4, gene: PTGER4)**, and **nivolumab (Opdivo)** is a monoclonal antibody immune checkpoint inhibitor targeting the **programmed cell death protein 1 (PD-1)** receptor. This combination seeks to modulate the tumor immune microenvironment by blocking both the prostaglandin E2 (PGE2) signaling pathway (which suppresses anti-tumor immunity) and the PD-1/PD-L1 axis (which inhibits T cell activation), thereby potentially enhancing anti-tumor immune responses in patients with advanced or refractory cancers. The combination is being developed by Bristol Myers Squibb for solid tumors including muscle-invasive bladder cancer and PD-L1 relapsed/refractory tumors[1][3][4][5][9].

Brand names

Opdivo

Other names

BMS-986310 + Opdivo